Literature DB >> 2580182

Captopril: contrasting effects of adding hydrochlorothiazide, propranolol, or nifedipine.

G A MacGregor, N D Markandu, S J Smith, G A Sagnella.   

Abstract

Because captopril alone does not control blood pressure in all patients with essential hypertension, studies were performed to assess the effect of sodium intake and of captopril combined with hydrochlorothiazide, propranolol, and nifedipine. Captopril given for 5 days to normotensive subjects having high, normal, and low sodium intakes reduced blood pressure the most in those on the lowest intake; the fall correlated with that in plasma angiotensin II. When 12 patients with moderate hypertension had hydrochlorothiazide added to captopril their blood pressure fell significantly. When propranolol was added to captopril, however, there was no further fall in blood pressure. When propranolol was added to captopril and a diuretic, pressures measured 4 and 6 h after the last dose of captopril showed reduced values compared with placebo; pressures measured 2 and 12 h after did not. Nifedipine added to captopril reduced blood pressure more than either drug alone. When renin and angiotensin are low, as they may be in essential hypertension, captopril is less effective; its effectiveness should increase if sodium is restricted. Both diuretics and nifedipine increase the effectiveness of captopril; propranolol does not, although it may prolong captopril's action. Experience in patients with resistant hypertension suggests that adding nifedipine to captopril may reduce the need for diuretics, while adding captopril to nifedipine may reduce the need for beta-blockers.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580182

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  20 in total

Review 1.  Resistant hypertension and the Birmingham Hypertension Square.

Authors:  D C Felmeden; G Y Lip
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

2.  The effects of combined angiotensin converting enzyme inhibition and beta-adrenoceptor blockade on plasma renin activity in anaesthetized dogs.

Authors:  D Cambridge; M V Whiting; L J Butterfield; G Allan
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

Review 3.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

4.  Dual blockade of the renin-angiotensin system with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

Review 5.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 6.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

7.  A single dose study of the effects of fenoldopam and enalapril in mild hypertension.

Authors:  T M MacDonald; R F Jeffrey; S Freestone; M R Lee
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 8.  ACE inhibitors. Drug interactions of clinical significance.

Authors:  C Mignat; T Unger
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

9.  The pharmacokinetic and pharmacodynamic interactions of ramipril with propranolol.

Authors:  J M van Griensven; M Seibert-Grafe; H C Schoemaker; M Frölich; A F Cohen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Converting-enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine.

Authors:  M Bellet; P Sassano; T Guyenne; P Corvol; J Menard
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.